🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Qingxin Mu

University of Washington

ORCID: 0000-0003-4952-6591

Also affiliated with Biodynamic Research Corporation (United States), Hua Medicine (China), Bruyère

Materials ScienceEngineeringBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 16 papers. Top paper: “Safety profile and cellular uptake of biotemplated nanocapsules with nanometre-thin walls”.

Safety profile and cellular uptake of biotemplated nanocapsules with nanometre-thin walls

Nanoscale(2011)10.1039/c1nr10311c

N/A

0.330DataRank · unranked

8 citations

Sergey A. Dergunov, Yi Zhang, Xi Li, Qingxin Mu, Qiu Zhang +4 more

In vivo serum enabled production of ultrafine nanotherapeutics for cancer treatment

Materials Today(2020)10.1016/j.mattod.2020.03.005

N/A

0DataRank · unranked

12 citations

Guanyou Lin, Zachary R. Stephen, Seokhwan Chung, Hui Wang, Victoria K. Patton +3 more

Optimizing a Novel Au-Grafted Lipid Nanoparticle Through Chelation Chemistry for High Photothermal Biologic Activity

Journal of Pharmaceutical Sciences(2020)10.1016/j.xphs.2020.02.010

N/A

0DataRank · unranked

5 citations

Qingxin Mu, Lisheng Zhu, Ziying Li, Rodney J. Y. Ho, Yu Gao

A highly selective iron oxide-based imaging nanoparticle for long-term monitoring of drug-induced tumor cell apoptosis

Biomaterials Science(2020)10.1039/d0bm00518e

N/A

0DataRank · unranked

5 citations

Qingxin Mu, Richard A. Revia, Zachary R. Stephen, Mike Jeon, Miqin Zhang +1 more

Computer-aided design of carbon nanotubes with the desired bioactivity and safety profiles

UNC Libraries(2020)10.17615/3523-ga22

N/A

0DataRank · unranked

0 citations

Liwen Li, Qingxin Mu, Denis Fourches, Bing Yan, Dongqiuye Pu +3 more

Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer

Materials Today(2021)10.1016/j.mattod.2021.08.002

N/A

0DataRank · unranked

74 citations

Guanyou Lin, Mike Jeon, Hui Wang, Fei‐Chien Chang, Richard A. Revia +3 more

ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models

Pharmaceutics(2021)10.3390/pharmaceutics14010089

N/A

0DataRank · unranked

18 citations

Qingxin Mu, Jesse Yu, James I. Griffin, Xiaolin Xu, Rodney J. Y. Ho +1 more

Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response

Pharmacology & Therapeutics(2022)10.1016/j.pharmthera.2022.108108

N/A

0DataRank · unranked

97 citations

Qingxin Mu, Millie Fung, Xiaolin Xu, Linxi Zhu, Rodney J. Y. Ho +1 more

Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis

PLoS ONE(2020)10.1371/journal.pone.0228557

N/A

0DataRank · unranked

13 citations

Jesse Yu, James I. Griffin, Yan Wu, Linxi Zhu, Lisa A. McConnachie +2 more

Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure

Pharmaceutics(2023)10.3390/pharmaceutics15031016

N/A

0DataRank · unranked

7 citations

Yan Wu, Qingxin Mu, Xinyan Li, Rodney J. Y. Ho, James I. Griffin

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

Frontiers in Oncology(2024)10.3389/fonc.2024.1393492

N/A

0DataRank · unranked

10 citations

Yu-Ting Chien, Zhiqian Chen, Qingxin Mu, Caroline B. Linde

Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies

PLoS ONE(2024)10.1371/journal.pone.0300723

N/A

0DataRank · unranked

4 citations

Xinyue Chen, Luqi Duan, Qingxin Mu, Rodney J. Y. Ho, James I. Griffin

An Efficient Fabrication Approach for Multi-Cancer Responsive Chemoimmuno Co-Delivery Nanoparticles

Pharmaceutics(2024)10.3390/pharmaceutics16101246

N/A

0DataRank · unranked

3 citations

Yu-Ting Chien, Qingxin Mu, Miqin Zhang, Jianxi Huang

Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression

Cancers(2024)10.3390/cancers16162792

N/A

0DataRank · unranked

1 citations

Xiaolin Xu, James I. Griffin, Qingxin Mu, Rodney J. Y. Ho, Jesse Yu

Editorial: Editor's challenge: Dr. Qingxin Mu - how can nanomedicine approaches advance multi-targeting strategy in combination cancer therapy?

Frontiers in Oncology(2024)10.3389/fonc.2024.1437497

N/A

0DataRank · unranked

0 citations

Qingxin Mu, Marina Pinheiro

Enzymatic and Cellular Degradation of Carbon-Based Biconcave Nanodisks

Micromachines(2022)10.3390/mi13071144

N/A

0DataRank · unranked

3 citations

Qingxin Mu, Hui Wang, Guanyou Lin, Miqin Zhang, Zhiyong Wei